|Day Low/High||67.58 / 68.31|
|52 Wk Low/High||64.18 / 88.16|
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
This big pharmaceutical player's recent woes could be good news for its rivals, but it also poses risks for investors.
Eli Lilly built up much false hope by being far too bullish on its now-failed Alzheimer treatment, Cramer said.
Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.
In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.
Jim Cramer ponders how this market simply can't stay down and also discusses how it isn't too late to get in.
'Milestone payments' could boost deal's $125 million announced price.
The worst appears to be over for this sector; we could see big growth ahead.
Cramer has learned what works and what doesn't at Action Alerts PLUS. Here's how his thinking can help you profit.
Eli Lilly said Wednesday that its experimental drug solanezumab failed to improve cognition of patients with mild Alzheimer's disease in a large Phase 3 clinical trial.
The Dow closed higher after the minutes from the Federal Reserve's policy-setting meeting indicate that an interest rate hike could come 'relatively soon.'
The Dow remains higher after the minutes from the Federal Reserve's policy-setting meeting indicate that an interest rate hike could come 'relatively soon.'
I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.
Here's a technical look on how to trade some of the most active stocks on the market today.
These 'wing and a prayer' stocks are full of surprises.
It will likely take several months of base building before LLY looks better on the charts.
Stocks trade mixed Wednesday as biotech shares tumble following a sharp drop in shares of Eli Lilly.
U.S. stocks pulled back Wednesday, from their record highs on Tuesday, when the Dow Jones Industrial Average crossed 19,000 and the S&P 500 topped 2,200.
Current Eli Lilly (LLY) CEO John C. Lechleiter and incoming CEO David Ricks reacted to the phase three testing failure of the company's Alzheimer's drug.
Stock futures fluctuate on Wednesday morning after a sharp increase in durable goods orders in October.
Based on the negative study results, Lilly will not pursue regulatory approvals for solanezumab in Alzheimer's disease.
Boehringer Ingelheim and Lilly launch For Your SweetHeart™, an educational campaign to help bridge knowledge gap and encourage people with type 2 diabetes to know their cardiovascular risk
Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.
In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.
- Results from an analysis of the landmark EMPA-REG OUTCOME® trial were presented today at the American Heart Association Scientific Sessions 2016